510(k) Report

510(k) · Cleared

Recalled · 2004

Mammotome EX Hand Held System

K033700510(k) TraditionalCleared Feb 20, 200487-day reviewClass II21 CFR 876.1075Recalls 1

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Ethicon Endo-Surgery, Inc. · KNW Instrument, Biopsy

Cleared on Feb 20, 2004 after an 87-day review. The FDA summary names its predicate without a number. 10 later devices descend from it. It has been recalled once.

Decided
Feb 20, 2004
Review
87 days
Class
Class II
Product code
KNW
Recalls
1
Predicates
0

10 later devices descend from it, 5 citing it directly.

Descendants, by year cleared 2012: 2 descendants cleared2006: 1 descendant cleared2016: 2 descendants cleared2008: 1 descendant cleared2019: 1 descendant cleared2020: 1 descendant cleared2018: 1 descendant cleared2022: 1 descendant cleared200020052010201520202025
  1. This deviceK033700 Mammotome EX Hand Held SystemEthicon Endo-Surgery, Inc. · 2004
  2. Descendant · cites it directly · 3 of its ownK112411 Mammotome Elite Biopsy SystemDevicor Medical Products, Inc. · 2012
  3. Descendant · 2 generations on · 2 of its ownK153709 Mammotome elite Biopsy System-13G Probe, Mammotome elite Biopsy…Devicor Medical Products, Inc. · 2016
  4. Descendant · cites it directly · 2 of its ownK123259 Mammotome Reolve Dual Vacuum Assisted Biopsy (Vab) SystemDevicor Medical Products, Inc. · 2012 · Recalled
  5. Descendant · cites it directly · 2 of its ownK060384 Coramate/Spirotome SystemMedinvents · 2006 · Recalled
  6. Descendant · cites it directly · 1 of its ownK152989 Mammotome revolve Dual Vacuum Assist Biopsy SystemDevicor Medical Products, Inc. · 2016 · Recalled

Showing 5 of 10 descendants. See all descendants

Descendants cleared per year

2006: 12008: 12012: 22016: 22018: 12019: 12020: 12022: 1
2006high 2 (2012) · low 0 (2007)2026

Most influential descendants

Showing 5 of 10 · See all
  • K112411Mammotome Elite Biopsy SystemDevicor Medical Products, Inc. · 2012 · cites it directly3descendants
  • K153709Mammotome elite Biopsy System-13G Probe, Mammotome elite Biopsy System-10G Probe…Devicor Medical Products, Inc. · 2016 · 2 generations on2descendants
  • K123259Mammotome Reolve Dual Vacuum Assisted Biopsy (Vab) SystemDevicor Medical Products, Inc. · 2012 · cites it directly2descendants
  • K060384Coramate/Spirotome SystemMedinvents · 2006 · cites it directly2descendants
  • K152989Mammotome revolve Dual Vacuum Assist Biopsy SystemDevicor Medical Products, Inc. · 2016 · cites it directly1descendant
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K033700Mammotome EX Hand Held SystemEthicon Endo-Surgery, Inc.2004—
+1K112411Mammotome Elite Biopsy SystemDevicor Medical Products, Inc.2012—
+2K153709Mammotome elite Biopsy System-13G Probe, Mammotome elite Biopsy System-10G…Devicor Medical Products, Inc.2016—
+1K123259Mammotome Reolve Dual Vacuum Assisted Biopsy (Vab) SystemDevicor Medical Products, Inc.20121
+1K060384Coramate/Spirotome SystemMedinvents20061
+1K152989Mammotome revolve Dual Vacuum Assist Biopsy SystemDevicor Medical Products, Inc.20161

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200610
200810
201220
201620
201810
201910
202010
202210
FIG. 1 — Lineage of K033700, 2004–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KNW? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new KNW device

  1. #1 K260572 Marrow Marxmanscore 14.5 · 10 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (3)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—Mammotome® Hand Held System
Named without a submission number
—
*—Mammotome® Hand Held 8 Gauge Probe
Named without a submission number
—
*—Mammotome® Biopsy System
Named without a submission number
—

What descends from it? (10)

5 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K112411Mammotome Elite Biopsy SystemDevicor Medical Products, Inc.20123
K123259Mammotome Reolve Dual Vacuum Assisted Biopsy (Vab) SystemDevicor Medical Products, Inc.20122
K060384Coramate/Spirotome SystemMedinvents20062
K152989Mammotome revolve Dual Vacuum Assist Biopsy SystemDevicor Medical Products, Inc.20161
K080095Coramate/Spirotome SystemMedinvents20081

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
Dec 10, 2004Not classifiedZ-0440-05OtherA capacitor of the wrong value was used. The capacitor used was 0.11 microfarad instead of 0.22 microfarad called for in the product specifications.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K112411 (Devicor Medical Products, Inc., 2012) has gone furthest, with 3 descendants of its own.

How does its category compare?

All KNW devices

KNW Instrument, Biopsy: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · KNW

12in 2025

2007: 62008: 42009: 62010: 32011: 102012: 72013: 32014: 82015: 102016: 92017: 82018: 72019: 52020: 82021: 92022: 82023: 72024: 52025: 122026 (partial year): 7
2007high 12 (2025) · low 3 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KNW

178in 2025

2007: 94 days median2008: 53 days median2009: 35 days median2010: 57 days median2011: 64 days median2012: 94 days median2013: 100 days median2014: 95 days median2015: 106 days median2016: 127 days median2017: 90 days median2018: 71 days median2019: 94 days median2020: 92 days median2021: 54 days median2022: 203 days median2023: 164 days median2024: 114 days median2025: 178 days median2026 (partial year): 29 days median
2007high 203 (2022) · low 35 (2009)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · KNW

1in 2024

2007: 12008: 72009: 32010: 22011: 52012: 12013: 1, 1 Class I2014: 32016: 52017: 12019: 42021: 32022: 32023: 22024: 12026 (partial year): 4, 3 Class I
2007high 7 (2008) · low 0 (2015)2026

Class I (4 since 2007) Class II/III not classified

Adverse event reports per year · KNW

1,667in 2025

2007: 7662008: 3632009: 3512010: 1622011: 672012: 932013: 982014: 1932015: 5912016: 2972017: 7602018: 1,0122019: 4,1952020: 5,1202021: 1,0202022: 5352023: 9312024: 1,2832025: 1,667
2007high 5,120 (2020) · low 67 (2011)2025

MAUDE reports naming product code KNW, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20076941766
20084537363
20096353351
20103572162
20111064567
2012794193
201331001 (1)98
20148953193
2015101060591
201691275297
20178901760
201877101,012
201959444,195
202089205,120
202195431,020
202282033535
202371642931
2024511411,283
20251217801,667
20267294 (3)—

What is it indicated for?

The Mammotome Biopsy System is indicated to provide tissue samples for diagnostic sampling of breast abnormalities. The Mammotome Biopsy System is intended to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality. The Mammotome Biopsy System is intended to provide breast tissue for histologic examination with partial removal of a palpable abnormality. The extent of a histologic abnormality cannot…

Read the full statement (205 words)

The Mammotome Biopsy System is indicated to provide tissue samples for diagnostic sampling of breast abnormalities.

The Mammotome Biopsy System is intended to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality.

The Mammotome Biopsy System is intended to provide breast tissue for histologic examination with partial removal of a palpable abnormality.

The extent of a histologic abnormality cannot always be readily determined from palpation or imaged appearance. Therefore, the extent of removal of the palpated or imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality, e.g., malignancy. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.

In instances when a patient presents with a palpable abnormality that has been classified as benign through clinical and/or radiological criteria (e.g., fibroadenoma, fibrocystic lesion), the Mammotome Biopsy System may also be used to partially remove such palpable lesions. Whenever breast tissue is removed, histological evaluation of the tissue is the standard of care. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K033700: Mammotome EX Hand Held System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K033700

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026